Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | APP | P05067 | 3/20 | 0.57 |
| ▸ | HRH1 | P35367 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19914447 | 0.94 | HRH3 (0.76) | HRH3LMNAALDH1A1TAAR1ALOX15 | |
| SCHEMBL31035900 | 0.93 | HRH3 (0.73) | HRH3LMNAALDH1A1TAAR1ALOX15 | |
| Betahistine SCHEMBL28346535 | 0.88 | HRH3 (1.00) | HRH3LMNAALDH1A1TAAR1ALOX15 | |
| Betahistine SCHEMBL125582 | 0.88 | HRH3 (1.00) | HRH3LMNAALDH1A1TAAR1ALOX15 | |
| Betahistine SCHEMBL29354603 | 0.88 | HRH3 (1.00) | HRH3LMNAALDH1A1TAAR1ALOX15 | |
| Betahistine SCHEMBL11315542 | 0.86 | HRH3 (0.96) | HRH3LMNAALDH1A1TAAR1ALOX15 | |
| Betahistine SCHEMBL20421889 | 0.86 | HRH3 (0.96) | HRH3LMNAALDH1A1TAAR1ALOX15 | |
| Betahistine SCHEMBL20421886 | 0.86 | HRH3 (0.96) | HRH3LMNAALDH1A1TAAR1ALOX15 | |
| Betahistine SCHEMBL20639365 | 0.86 | HRH3 (0.96) | HRH3LMNAALDH1A1TAAR1ALOX15 | |
| Betahistine SCHEMBL60646 | 0.86 | LMNA (1.00) | HRH3LMNAALDH1A1TAAR1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558965-A1 | NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-10-30 | — | — | EP | claimed |
| WO-2018115064-A1 | NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2018-06-28 | — | — | WO | claimed |
| US-6255288-B1 | THERAPY FOR BONE DISORDERS | NOVARTIS CORPORATION | 2001-07-03 | — | — | US | claimed |
| EP-0600834-A1 | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | claimed |
| EP-0550385-A1 | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers | CIBA-GEIGY AG (CH) | 1993-07-07 | — | — | EP | claimed |
| EP-0407344-A2 | Pharmaceutical preparation for topical application | CIBA-GEIGY AG (CH) | 1991-01-09 | — | — | EP | claimed |
| US-11685722-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20200407329-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2020-12-31 | — | — | US | disclosed |
| WO-2020247575-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-3558965-A1 | NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-10-30 | — | — | EP | disclosed |
| WO-2019182474-A1 | BUSPIRONE COMBINATIONS FOR TREATING DIZZINESS | Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" | 2019-09-26 | — | — | WO | disclosed |
| WO-2018115064-A1 | NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018039621-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-6255288-B1 | THERAPY FOR BONE DISORDERS | NOVARTIS CORPORATION | 2001-07-03 | — | — | US | disclosed |
| US-6057306-A | ADMINISTERING BISPHOSPHONATES TO TREAT BONE DISEASE | NOVARTIS CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0600834-A1 | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | disclosed |
| US-5296475-A | Methanediphosphonic acids and crown compounds for treatment of bone disorders or hypercalcemia | CIBA-GEIGY CORPORATION (US) | 1994-03-22 | — | — | US | disclosed |
| EP-0550385-A1 | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers | CIBA-GEIGY AG (CH) | 1993-07-07 | — | — | EP | disclosed |
| US-5133972-A | TOPICALLY ADMINISTRABLE PHARMACEUTICAL PREPARATIONS | CIBA-GEIGY CORPORATION (US) | 1992-07-28 | — | — | US | disclosed |
| EP-0407344-A2 | Pharmaceutical preparation for topical application | CIBA-GEIGY AG (CH) | 1991-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685722-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | HRH3 4049/4885LMNA 4459/4885ALDH1A1 1478/4885 |
| US-20200407329-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | HRH3 4049/4885LMNA 4459/4885ALDH1A1 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.